Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7

J. Rubin, E. Galanis, H. C. Pitot, R. L. Richardson, P. A. Burch, J. W. Charboneau, C. C. Reading, B. D. Lewis, S. Stahl, E. T. Akporiaye, David T. Harris

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

We have completed a phase I study to test feasibility and toxicity of immunotherapy of hepatic metastases from colorectal carcinoma by direct gene transfer of HLA-B7, a MHC class I gene. Eligible patients were HLA-B7 negative, immunocompetent by PHA lymphocyte stimulation and had at least two measurable hepatic lesions on CT scan for measurement of response of the injected lesion, as well as evaluation of possible distant response. Under ultrasonographic guidance the hepatic lesions were injected with Allovectin-7, a liposomal vector containing the combination of the HLA-B7 gene with β2-microglobulin formulated with the lipid DMRIE-DOPE. Eligible patients were injected on two schedules. On the first schedule patients received an injection on day 1 and the injected lesion was biopsied to determine transfection every 2 weeks for 8 weeks. Doses were escalated from 10 μg to 50 μg to 250 μg with three patients treated at each level. The second schedule included multiple injections of 10 μg. Three patients received injections on days 1 and 15. Three patients received injections on days 1, 15 and 29. A total of 15 patients have completed treatment. The plasmid DNA was detected in 14 of 15 patients (93%) by PCR. In five of 15 patients (33%) mRNA was also detected. The HLA-B7 protein was detected in five of eight patients (63%) by immunohistochemistry and in seven of 14 patients (50%) tested by fluorescence activated cell sorting (FACS) analysis. There has been no serious toxicity directly attributable to allovectin-7. Our results suggest that liposomal gene transfer by direct injection is feasible and non-toxic. Further studies will be necessary in order to establish the therapeutic efficacy.

Original languageEnglish (US)
Pages (from-to)419-425
Number of pages7
JournalGene Therapy
Volume4
Issue number5
StatePublished - 1997

Fingerprint

HLA-B7 Antigen
Histocompatibility Antigens
Immunotherapy
Colorectal Neoplasms
Neoplasm Metastasis
Liver
Genes
Injections
Appointments and Schedules
MHC Class I Genes
Toxicity Tests
Lymphocyte Activation
Transfection
Flow Cytometry
Plasmids
Immunohistochemistry

Keywords

  • Colorectal carcinoma
  • Gene therapy
  • HLA-B7
  • Immunotherapy
  • Lipid vector

ASJC Scopus subject areas

  • Genetics

Cite this

Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. / Rubin, J.; Galanis, E.; Pitot, H. C.; Richardson, R. L.; Burch, P. A.; Charboneau, J. W.; Reading, C. C.; Lewis, B. D.; Stahl, S.; Akporiaye, E. T.; Harris, David T.

In: Gene Therapy, Vol. 4, No. 5, 1997, p. 419-425.

Research output: Contribution to journalArticle

Rubin, J, Galanis, E, Pitot, HC, Richardson, RL, Burch, PA, Charboneau, JW, Reading, CC, Lewis, BD, Stahl, S, Akporiaye, ET & Harris, DT 1997, 'Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7', Gene Therapy, vol. 4, no. 5, pp. 419-425.
Rubin, J. ; Galanis, E. ; Pitot, H. C. ; Richardson, R. L. ; Burch, P. A. ; Charboneau, J. W. ; Reading, C. C. ; Lewis, B. D. ; Stahl, S. ; Akporiaye, E. T. ; Harris, David T. / Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. In: Gene Therapy. 1997 ; Vol. 4, No. 5. pp. 419-425.
@article{1882c46702a44502838bb8f46b1db117,
title = "Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7",
abstract = "We have completed a phase I study to test feasibility and toxicity of immunotherapy of hepatic metastases from colorectal carcinoma by direct gene transfer of HLA-B7, a MHC class I gene. Eligible patients were HLA-B7 negative, immunocompetent by PHA lymphocyte stimulation and had at least two measurable hepatic lesions on CT scan for measurement of response of the injected lesion, as well as evaluation of possible distant response. Under ultrasonographic guidance the hepatic lesions were injected with Allovectin-7, a liposomal vector containing the combination of the HLA-B7 gene with β2-microglobulin formulated with the lipid DMRIE-DOPE. Eligible patients were injected on two schedules. On the first schedule patients received an injection on day 1 and the injected lesion was biopsied to determine transfection every 2 weeks for 8 weeks. Doses were escalated from 10 μg to 50 μg to 250 μg with three patients treated at each level. The second schedule included multiple injections of 10 μg. Three patients received injections on days 1 and 15. Three patients received injections on days 1, 15 and 29. A total of 15 patients have completed treatment. The plasmid DNA was detected in 14 of 15 patients (93{\%}) by PCR. In five of 15 patients (33{\%}) mRNA was also detected. The HLA-B7 protein was detected in five of eight patients (63{\%}) by immunohistochemistry and in seven of 14 patients (50{\%}) tested by fluorescence activated cell sorting (FACS) analysis. There has been no serious toxicity directly attributable to allovectin-7. Our results suggest that liposomal gene transfer by direct injection is feasible and non-toxic. Further studies will be necessary in order to establish the therapeutic efficacy.",
keywords = "Colorectal carcinoma, Gene therapy, HLA-B7, Immunotherapy, Lipid vector",
author = "J. Rubin and E. Galanis and Pitot, {H. C.} and Richardson, {R. L.} and Burch, {P. A.} and Charboneau, {J. W.} and Reading, {C. C.} and Lewis, {B. D.} and S. Stahl and Akporiaye, {E. T.} and Harris, {David T.}",
year = "1997",
language = "English (US)",
volume = "4",
pages = "419--425",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7

AU - Rubin, J.

AU - Galanis, E.

AU - Pitot, H. C.

AU - Richardson, R. L.

AU - Burch, P. A.

AU - Charboneau, J. W.

AU - Reading, C. C.

AU - Lewis, B. D.

AU - Stahl, S.

AU - Akporiaye, E. T.

AU - Harris, David T.

PY - 1997

Y1 - 1997

N2 - We have completed a phase I study to test feasibility and toxicity of immunotherapy of hepatic metastases from colorectal carcinoma by direct gene transfer of HLA-B7, a MHC class I gene. Eligible patients were HLA-B7 negative, immunocompetent by PHA lymphocyte stimulation and had at least two measurable hepatic lesions on CT scan for measurement of response of the injected lesion, as well as evaluation of possible distant response. Under ultrasonographic guidance the hepatic lesions were injected with Allovectin-7, a liposomal vector containing the combination of the HLA-B7 gene with β2-microglobulin formulated with the lipid DMRIE-DOPE. Eligible patients were injected on two schedules. On the first schedule patients received an injection on day 1 and the injected lesion was biopsied to determine transfection every 2 weeks for 8 weeks. Doses were escalated from 10 μg to 50 μg to 250 μg with three patients treated at each level. The second schedule included multiple injections of 10 μg. Three patients received injections on days 1 and 15. Three patients received injections on days 1, 15 and 29. A total of 15 patients have completed treatment. The plasmid DNA was detected in 14 of 15 patients (93%) by PCR. In five of 15 patients (33%) mRNA was also detected. The HLA-B7 protein was detected in five of eight patients (63%) by immunohistochemistry and in seven of 14 patients (50%) tested by fluorescence activated cell sorting (FACS) analysis. There has been no serious toxicity directly attributable to allovectin-7. Our results suggest that liposomal gene transfer by direct injection is feasible and non-toxic. Further studies will be necessary in order to establish the therapeutic efficacy.

AB - We have completed a phase I study to test feasibility and toxicity of immunotherapy of hepatic metastases from colorectal carcinoma by direct gene transfer of HLA-B7, a MHC class I gene. Eligible patients were HLA-B7 negative, immunocompetent by PHA lymphocyte stimulation and had at least two measurable hepatic lesions on CT scan for measurement of response of the injected lesion, as well as evaluation of possible distant response. Under ultrasonographic guidance the hepatic lesions were injected with Allovectin-7, a liposomal vector containing the combination of the HLA-B7 gene with β2-microglobulin formulated with the lipid DMRIE-DOPE. Eligible patients were injected on two schedules. On the first schedule patients received an injection on day 1 and the injected lesion was biopsied to determine transfection every 2 weeks for 8 weeks. Doses were escalated from 10 μg to 50 μg to 250 μg with three patients treated at each level. The second schedule included multiple injections of 10 μg. Three patients received injections on days 1 and 15. Three patients received injections on days 1, 15 and 29. A total of 15 patients have completed treatment. The plasmid DNA was detected in 14 of 15 patients (93%) by PCR. In five of 15 patients (33%) mRNA was also detected. The HLA-B7 protein was detected in five of eight patients (63%) by immunohistochemistry and in seven of 14 patients (50%) tested by fluorescence activated cell sorting (FACS) analysis. There has been no serious toxicity directly attributable to allovectin-7. Our results suggest that liposomal gene transfer by direct injection is feasible and non-toxic. Further studies will be necessary in order to establish the therapeutic efficacy.

KW - Colorectal carcinoma

KW - Gene therapy

KW - HLA-B7

KW - Immunotherapy

KW - Lipid vector

UR - http://www.scopus.com/inward/record.url?scp=8244224532&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244224532&partnerID=8YFLogxK

M3 - Article

C2 - 9274718

AN - SCOPUS:8244224532

VL - 4

SP - 419

EP - 425

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 5

ER -